Investing Observation & Opinion


  • Economy & Politics
  • Investing
  • Personal Finance
  • Related Posts

    Barnes & Noble Founder Offloads $64m
    Weibo Shares Surge On US Debut
    London Market Report
    China Sales Fall Hits Remy Cointreau
    China ‘Must Allow Currency To Rise’
    Mutual Funds Are Bypassing IPOs And Going Straight For The Main Course
    The Great Stock Buyback Craze Is Finally Ending
    WTF Moment Of The Week: No One Bought Japanese Bonds For 36 Hours This Week
    Big Blue: Stock Buyback Machine On Steroids
    BP Oil Spill Crisis Manager Managed Crisis By Selling BP Stock
    Morgan Stanley’s Bond-Market Magic
    How Can Yahoo Be Worth Less Than Zero?
    Tech Workers Seek To Use Steve Jobs Evidence In Upcoming Trial On No-hire Accords
    The Robot Is Ready — So When Will Deep Sea Mining Start?
    Retailer Michaels Stores Confirms Payment Card Data Breach

    The Next Move In The 1,000 Percent-Plus Biotech Bull Market Starts Now

    Biotech stocks have an incredible history of delivering quadruple-digit runs about once a decade.

    It’s stunning, really. In the late 1980s, biotech stocks took off, returning 3,246 percent in just a couple years. In the late 1990s, biotech stocks took off again, returning 1,523 percent in an even shorter period of time.

    I think we’re in the early stages of a similar run today.

    Biotech stocks had a huge year last year.

    The Nasdaq Biotechnology Index increased 32.3 percent — more than double the overall stock market return. By investing in a double-long fund, my True Wealth Systems readers were able to lock in a 56 percent gain from January to November. 

    Even after that run, our setup in biotech stocks is still fantastic today. Let me explain.

    I use my True Wealth Systems service to determine when it’s time to buy biotech stocks. Today, my biotech system is flashing a "buy" signal. In short, the trend in biotech stocks is up.

    Meanwhile, the investing public is completely ignoring the opportunity in biotech.

    You see, back in 2000 — after biotech stocks had soared 1,523 percent in less than three years — biotech CEOs were on magazine covers. They even had sexy headlines. No joke.

    The July 2000 issue of Time magazine ran the headline "Cracking the Code: The inside story of how these bitter rivals mapped our DNA, the historic feat that changes medicine forever." 

    I haven’t seen a sexy biotech headline in a major magazine in a while. And that lack of interest from the mainstream press suits me just fine.

    Disinterest in biotech stocks has led to cheap prices. The major biotech stocks are growing much faster than the overall stock market. But they’re cheaper, based on 2014 estimated price-to-earnings (P/E) ratios.

    The Nasdaq Biotechnology Index is also 77 percent below its peak valuation based on price-to-sales ratios.

    The Nasdaq Biotech Index is 77% Below Its Valuation High

    Investors have given up on biotech stocks, and these companies are dirt-cheap because of it. Yet biotech is in the middle of an uptrend. Based on history, we could be just partway into a 1,000 percent-plus move in biotech stocks.

    In True Wealth Systems, we invest using the ProShares Ultra Nasdaq Biotechnology fund (BIB). Keep in mind that this is a double-long fund. So while the up days will be twice as good, the down days will be twice as bad.

    Our True Wealth Systems computers believe now is the time to own biotech.

    The sector is cheap, ignored and in an uptrend. Quadruple-digit runs in biotech happen roughly once a decade. And we may be in the middle of another one of those 1,000 percent-plus runs right now. 

    Take a look at BIB today if you aren’t already in the trade. We expect another year of fantastic gains.

    Good investing, 


    Editor’s note: If you’d like more insight and actionable advice from Dr. Steve Sjuggerud, consider a free subscription to DailyWealth. Sign up for DailyWealth here and receive a report on the "Ultimate Agriculture Investment." You’ve likely never considered this "alternative" asset, but it has consistently beaten stocks and bonds over the past 30 years. Click here to learn more.

    Dr. Steve Sjuggerud is the founder and editor of one of the largest financial newsletters in the world, True Wealth. Since inception in 2001, True Wealth readers have made money every year with safe, contrarian investment ideas. Steve did his Ph.D. dissertation on international currencies, he's traveled to dozens of countries looking at investment ideas, and he's run mutual funds, hedge funds, and investment research departments. Steve's investment philosophy is simple: "You buy something of extraordinary value at a time when nobody else wants it. And you sell it at a time when people are willing to pay any price to get it." It's harder than it sounds, but Steve continues to be able to do just that for his readers. Click here to learn more.

    | All posts from Dr. Steve Sjuggerud

    Discuss this Story:

    Comment Policy: We encourage open discussion. Comments including racist statements, profanity, name calling or spam will be removed at our discretion. We use filters for spam protection. If your comment does not appear it is likely because it violates the policy.

    U.S. Judge Declines To Order ‘Park It Now’ Notices For GM Cars
    BlackRock’s Quarterly Profit Climbs As Investors Pile Into Funds
    This Tech Startup Uses A Simple Formula To Decide How Much Stock To Give Employees
    Your Precious Chipotle Burrito Is About To Get More Expensive
    Million-Mile View Of Investment Value
    Why Beating The Market Is An Uphill Skate
    Shipping Firms Turn To Equity Markets As Sector Eyes Recovery
    3 Big Retail Trends To Watch For
    At Macy’s, Lessons From Walmart’s Failed RFID Attempt
    Welcome To The Unfriendly Skies
    Is Bitcoin Like High-Speed Trading?
    Meet The Guy Who Helped Add $2 Billion To Twitter’s Valuation Yesterday
    Bank Of America’s Legal Woes Are Only Partly To Blame For Its Disappointing Quarter
    Metals Stocks: Gold Wavers, Copper Edges Up After China Data
    The Best Online Tools To Track Your Investments
    How To Profit By Avoiding Common Investment Errors
    Beware Of The Walking Dead In Your Portfolio
    SodaStream Pops 11% On Minority Stake Sale Buzz
    Yahoo Shares A Good Buy As Alibaba Nears IPO: Analysts
    Mrs. Fields Looks Beyond The Mall
    Europe’s Gentle Clampdown On Flash Boys
    Do You See A Bubble?
    Homebuilder Confidence Misses For 4th Month In A Row
    Stocks Move Higher On Encouraging Profit Reports
    Here’s How Box Can Still Go Public In The Midst Of The Brutal Tech Selloff
    Stocks That Go Up Can Keep Going Up
    Nestle Reports Slow First Quarter
    China Gold Demand ‘On The Rise’
    Don’t Just Sit On Your Investments, Do Something
    Should Google Know Your Deepest Darkest Secrets?
    Read more from Investing...

    Liberty Investor Digest

    Get today's most important
    financial headlines all in
    one place by email!



    Sign Up For Liberty Investor Digest™!

    Get Liberty Investor Digest FREE By Email!

    Input your name and email address in the fields below and get today's most important financial headlines sent straight to you inbox!

    Privacy PolicyYou can opt-out at any time. We protect your information like a mother hen. We will not sell or rent your email address to anyone for any reason.